focus -WSS

focus

author：Wikipedia 2025-09-27 22:47:06 - browse：6972

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： New company forms to vet health AI models, root out weaknesses

focus

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Vertigo drug brings hope for rare neuron disorder, Niemann

Medical mystery: When an infection after surgery isn’t what it seems

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Vertex non

Medicare proposal to cover medical devices draws a mixed reaction

Biden administration opens offers in Medicare drug price negotiations

Trump demands the U.S. pay no more for drugs than other countries … again

Woodcock on FDA’s accelerated approval and her next chapter

Walensky prepares to leave CDC — and Congress — behind

General Catalyst, Summa Health deal will turn on physician buy

Drug repurposing or repositioning? The language matters

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

leisure time

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

Eat, drink, but be wary — 4 foods that interact with medications

General Catalyst, Summa Health deal will turn on physician buy

Eat, drink, but be wary — 4 foods that interact with medications

entertainment

focus

focus

Wikipedia